Strengths and Weaknesses of Immunotherapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of 12 Randomized Controlled Trials

BACKGROUND: Lung cancer is one of the leading causes of cancer death worldwide. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Immunotherapy has yielded no consistent benefit to date for those patients. Assessing the objective efficacy and safety of immunother...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Juan, Zou, Ze-Hong, Xia, Hong-Lin, He, Jian-Xing, Zhong, Nan-Shan, Tao, Ai-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293858/
https://www.ncbi.nlm.nih.gov/pubmed/22403699
http://dx.doi.org/10.1371/journal.pone.0032695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293858/
https://www.ncbi.nlm.nih.gov/pubmed/22403699
http://dx.doi.org/10.1371/journal.pone.0032695

Ejemplares similares